Success of Clinical Trials for COVID-19 Vaccines Boosts Market Growth

The coronavirus pandemic has brought research labs and healthcare institutions under great scrutiny for accelerating the clinical trials for COVID-19 vaccines. As such, the success in these clinical trials has led to global recognition of India for supplying several lack of free doses to Brazil, Bangladesh, Algeria, and South Africa. Countries such as Sri Lanka are following suit whilst creating incremental opportunities for stakeholders in the clinical trials market.

The Food & Drug Administration (FDA) is creating awareness about Coronavirus Treatment Acceleration Program (CTAP) in order to bring economies to normal. Companies in the clinical trials market are taking advantage of this program to make new treatments available to patients as quickly as possible.

clinical trials market segmentation

To know the scope of our report Get a Sample on Clinical Trials Market

Clinical Trial Recruitment Companies Essential for Matching Patients with Right Trial

The clinical trials market is estimated to cross US$ 83.5 Bn by the end of 2030. However, finding the right patients is one of the most important pieces of the puzzle with respect to conducting clinical trials. Hence, stakeholders are working with experts at clinical trial recruitment companies to match patients with the right trials.

Slow recruitment is another challenge faced by companies in the clinical trials market. Hence, companies are becoming aware about scrutinizing existing patient data to anticipate potential recruitment challenges in the long run. Clinical trial innovations are anticipated to bolster participation from volunteers.

Get a glimpse of the in-depth analysis through our Report Brochure

FDA Guidelines Pave Way for Innovations for At-home, At-clinic Clinical Trials

Companies in the clinical trials market are following guidelines of the FDA to advance in processes. They are referring to FDA guidance about Severely Debilitating or Life-Threatening Hematologic Disorders (SDLTHDs) in patients. Companies are increasing efforts to fill in the gap between scientific and technical complexities of clinical trials. Thus, companies are investing in improving the academia and are developing new incentives that reward collaboration from volunteers.

Companies in the clinical trials market are taking additional efforts to develop networks that enable procedures at a patient’s home or at their private doctor’s clinic. This has led to innovations in sensor devices, patient reported outcomes on their computers, and flash pictures of their lesions from their cellphones that contribute toward processes.

Coronavirus Pandemic Pushes Sponsors, Patients to Adopt Virtual Clinical Trials

Compliance with protocols is one of the key trends followed by stakeholders in the clinical trials market. Clinical trials supervised by Principal Investigators are gaining prominence in the market landscape. Continued positive cases for coronavirus have increased relevancy and role of stakeholders in the clinical trials market. This shift has pushed clinical trials to go virtual.

Stakeholders in the clinical trials market are teaming up with virtual clinical trial experts to capitalize on business opportunities during the ongoing pandemic. Even regulatory authorities have released guidelines to assist sponsors and patients via telemedicine and virtual trial tools to create viable solutions for current operational problems.

Digital Health Innovations Give Impetus to IoMT for Enhancing Clinical Development Programs

The proliferation of digital innovations with the help of wearables and sensors is translating into value grab opportunities for companies in the clinical trials market. ICON plc— a clinical research organization company is researching how digital endpoints, including digital biomarkers can improve trial outcomes. This has led to the adoption of digital health technologies that enable appropriate device selection and data strategies.

Digital health innovations hold promising potentials to better manage chronic diseases and improve patient access to healthcare services. Stakeholders and sponsors are taking efforts to improve adherence to medications and prevent its complications in patients. The Internet of Medical Things (IoMT) has the potential to enhance clinical development programs involving med-tech and pharmaceutical companies.

clinical trials market infographic

Expanding operations in future? To get the perfect launch ask for a custom report 

Analysts’ Viewpoint

There is a need for trial innovations since recently several volunteers were given wrong dose of the late stage clinical trial of the Oxford/AstraZeneca Covid-19 vaccine. The clinical trials market is predicted to advance at a modest CAGR of ~5% during the forecast period. This is evident since stakeholders need to address challenges pertaining to site management and compliance in order to improve trial outcomes. Hence, companies are developing clinical trial timelines to avoid delays, and are increasing transparency with their sponsors to offer them a 360 degree view of the processes happening at development centers. IoMT is acting as a key driver for the market.

Clinical Trials Market: Overview

  • According to Transparency Market Research’s latest report on the global clinical trials market for the historical period 2018–2019 and forecast period 2020–2030, high prevalence and increase in incidence rate of chronic diseases and rise in R&D activities in biotechnology & pharmaceuticals industries are projected to drive the global clinical trials market during the forecast period
  • According to the report, the global clinical trials market was valued over US$ 46.7 Bn in 2019 and is anticipated to expand at a CAGR of ~5% from 2020 to 2030

High Prevalence and Increase in Incidence Rate of Chronic Diseases to Drive Demand for Clinical Trials: Key Drivers

  • Chronic diseases such as chronic respiratory diseases (CRD), diabetes, chronic kidney diseases (CKD), cancer, cardiac stroke, and neurological disorders are the leading causes of disability and mortality across the globe
  • The emergence and outbreak of various infectious and chronic diseases have created challenges and new opportunities for researchers to develop new diagnostic tools, tests, drugs, and vaccines for early diagnosis, prevention, and cure of such diseases
  • Hepatitis and HIV are the other major infectious diseases. According to the World Health Organization (WHO), as of October 2017, around 71 million people across the world were estimated to have hepatitis C infection. The WHO also stated that 36.7 million people were affected with HIV across the globe.
  • An article published by Columbia, Mailman School of Public Health on infectious disease epidemiology stated that infectious diseases continue to have a substantial impact on the health of communities across the world. Various seasonal outbreaks of diseases in certain parts of the world, global epidemics, the threat of resistant bacteria, and the challenge of emerging and newly identified pathogens increase the need of new methods to detect such pathogens, to understand their pathogenesis, and to devise effective interventions for their prevention and control.
  • These factors have led to an increase in demand for clinical trials, and are expected to drive the clinical trials market from 2020 to 2030

Rise in R&D Activities in Biotechnology and Pharmaceuticals Industries Boosts Market Growth

  • Clinical research organizations, diagnostic laboratories, and biotechnology players are engaged in the development of newer diagnostic tests to address the unmet needs in the healthcare industry. The life science industry’s R&D spending is driven primarily by the mass and research intensity of the biopharmaceutical sector, which accounts for nearly 85% of all expenditure.
  • Additionally, laboratories strive to improve equipment cost and performance. UHPLC and ultra-fast mass spectrometers are more reliable, faster, and more sensitive as a result of research initiatives by major players.
  • Acceleration in biopharmaceutical R&D innovation, buoyed by several contributing factors such as precision medicine getting into gear in rare diseases, cancer, and autoimmune diseases; immunotherapy, expansion of therapeutic modalities exploiting natural and synthetic biology innovation, and expedited regulatory pathways boost the growth of the clinical trials market

Patient Recruitment and Retention to Hamper Global Market

  • Shift in focus toward genetic and rare diseases has made recruitment of relevant patient population a challenging task. Moreover, lack of awareness among patients of clinical trials presents a challenging environment for CROs.
  • Lack of appropriate patient recruitment could have an impact on the scientific and financial viability. According to the Tufts Center for the Study of Drug Development, in 2013, 11% of the sites failed to recruit even a single patient for clinical trial.
  • Other factors responsible for poor patient recruitment are patient’s fear of side effects, illiteracy, language barrier for region-specific clinical trials, and recording of the consent process
  • Factors affecting the retention of patients for clinical trials include serious adverse events, fear of complex medical procedures, poor compliance of protocol, lack of dedication toward patient safety, and lack of support from family. This significantly affects the advancement of clinical trial process and product development.

Clinical Trials Market: Competition Landscape

  • This report profiles major players in the global clinical trials market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • Leading players operating in the global clinical trials market are
    • Laboratory Corporation of America Holdings
    • IQVIA, Inc.
    • Syneos Health
    • Parexel International Corporation
    • PRA Health Sciences, Inc.
    • PPD, Inc.
    • Icon plc
    • Charles River Laboratories, Inc.
    • WuXi AppTec
    • Medpace Holdings, Inc.

Clinical Trials Market: Key Developments

  • Key players in the global clinical trials market are engaged in regulatory approvals, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global clinical trials market. Few expansion strategies adopted by players operating in the global clinical trials market are:
    • In February 2020, Charles River Laboratories International, Inc. signed an agreement to acquire Citoxlab for US$ 510 Mn. Citoxlab is a non-clinical CRO specialized in regulated safety assessment services, non-regulated discovery services, and medical device testing.
    • In November 2019, PPD, Inc. launched site coach where doctors and healthcare centers will receive clinical research at new sites, which will provide sufficient training for physicians and other academic institutions through online for the new clinical researchers
    • In October 2019, Icon plc acquired Symphony Clinical Research to enhance the ability in offering customers hybrid trial solutions and site support services. This acquisition affected the clinical trials directly and improved the services in the research centers.
    • In June 2019, Laboratory Corporation’s Covance Drug Development segment completed the acquisition of Envigo’s nonclinical contract research services business. This acquisition enabled the company to increase its global nonclinical drug development capabilities. As part of this move, Envigo acquired Covance’s research models & services business, leading to the establishment of an organization dedicated to offering a complete range of research models.
    • In October 2018, Parexel International Corporation announced that it would launch new wearable, mobile tech for clinical trials, which will expand the services in clinical research. Microsoft's Azure App Services is one of the mobile tech services, which alerts a healthcare team when there is a patient safety threat.
    • In February 2018, PPD, Inc. and Acurian introduced an innovative clinical trial patient concierge service that provides personalized patient support and improves customer retention. PPD’s Site Coach Service addresses this by providing specialized clinical research education, coaching, and support to new clinical research physicians, hospitals, and academic institutions.
    • In April 2018, ICON plc, a global biopharmaceutical company, announced that it recently agreed with the Intel Pharma Analytics platform in clinical trials, which will help to reduce costs in clinical trials and delivers an excellent patient experience
    • In August 2017, LabCorp, a leading company in life sciences, acquired Chiltren for around US$ 1.2 Bn. The company enhanced end-to-end drug development services and engaged patient care more effectively in the next few years.
    • In May 2017, WuXi AppTec Co., Ltd. announced completion of the acquisition of HD Biosciences (HDB), a leading biology-focused preclinical drug discovery contract research organization (CRO). The acquisition would further strengthen WuXi’s R&D capability from target validation to lead discovery and optimization, improving and expanding WuXi’s open-access enabling service platform.
    • In June 2016, IQVIA, the most significant research organization, launched a continuous glucose monitoring device, which is helpful to record a person's glucose levels throughout the day. Medical device CGM is combined with the consumer wearable devices to record the readings.
    • In June 2015, IQVIA and PRA Health Sciences, two leading companies in pharmaceuticals, announced that with new predictive and advanced analytics technology they plan to improve the performance in clinical trials and improve safety issues
    • In October 2014, Laboratory Corporation of America Holdings acquired Covance, Inc. for US$ 5.6 Bn and became world’s leading health care diagnostic company and leading end-to-end solutions provider for drug development and commercialization
  • The report on the global clinical trials market discussed individual strategies, followed by company profiles of service providers of clinical trials. The competition landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global clinical trials market.

Clinical Trials Market – Scope of the Report

TMR’s report on the global clinical trials market studies the past as well as the current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period from 2020 to 2030. The report provides the overall revenue of the global clinical trials market for the period 2018–2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) of the global clinical trials market for the forecast period from 2020–2030.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the clinical trials market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various phenomena in the global clinical trials market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the clinical trials market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the clinical trials market.

The report delves into the competition landscape of the global clinical trials market. Key players operating in the clinical trials market have been identified and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the clinical trials market profiled in this report.

Key Questions Answered in Clinical trials Market Report

  • How does the development of clinical trials provide scope of growth in the global clinical trials market?
  • How alliances and partnerships between players are widening the scope of new line of technologies for clinical trials?
  • What are the revenue share projections of key segments under various criteria in the clinical trials market during the forecast period?
  • Which segment is likely to register leading revenue until the end of the forecast period in 2030?

Clinical Trials Market – Research Objectives and Research Approach

The comprehensive report on the global clinical trials market begins with an overview of the market, followed by the scope and objectives of this study. Following this, the report provides detailed explanation of the objectives behind this study and healthcare compliances laid down by accredited agencies in the purview of line of procedure for clinical trials.

For reading comprehensibility, the report is compiled in a chapter-wise layout, with each section further divided into smaller ones. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the clinical trials market in terms of phase, study design, indication, and region. Key segments under each criteria are studied at length, and the market share for each of these at the end of 2030 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global clinical trials market.

Clinical Trials Market – Segmentation

Phase

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Study Design

  • Interventional Trials
  • Observational Trials
  • Expanded Access Trials
Indication
  • Autoimmune/Inflammation
  • Pain Management
  • Cardiovascular
  • CNS Condition
  • Oncology
  • Diabetes
  • Obesity
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Clinical Trials Market

4. Market Overview

    4.1. Introduction

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Clinical Trials Market Analysis and Forecast, 2018–2030

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Number of Clinical Trials

    5.2. Key Industry Events

    5.3. COVID-19 Pandemic Impact on Industry

6. Global Clinical Trials Market Analysis and Forecast, by Phase 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Phase, 2018–2030

        6.3.1. Phase I

        6.3.2. Phase II

        6.3.3. Phase III

        6.3.4. Phase IV

    6.4. Market Attractiveness Analysis, by Phase 

7. Global Clinical Trials Market Analysis and Forecast, by Study Design 

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Study Design, 2018–2030

        7.3.1. Interventional Trials

        7.3.2. Observational Trials

        7.3.3. Expanded Access Trials

    7.4. Market Attractiveness Analysis, by Study Design 

8. Global Clinical Trials Market Analysis and Forecast, by Indication 

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Indication, 2018–2030

        8.3.1. Autoimmune/Inflammation

        8.3.2. Pain Management

        8.3.3. Cardiovascular

        8.3.4. CNS Condition

        8.3.5. Oncology

        8.3.6. Diabetes

        8.3.7. Obesity

        8.3.8. Others

    8.4. Market Attractiveness Analysis, by Indication 

9. Global Clinical Trials Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America 

        9.2.2. Europe 

        9.2.3. Asia Pacific

        9.2.4. Latin America 

        9.2.5. Middle East & Africa 

    9.3. Market Attractiveness Analysis, by Country/Region

10. North America Clinical Trials Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Phase, 2018–2030

        10.2.1. Phase I

        10.2.2. Phase II

        10.2.3. Phase III

        10.2.4. Phase IV

    10.3. Market Value Forecast, by Study Design, 2018–2030

        10.3.1. Interventional Trials

        10.3.2. Observational Trials

        10.3.3. Expanded Access Trials

    10.4. Market Value Forecast, by Indication, 2018–2030

        10.4.1. Autoimmune/Inflammation

        10.4.2. Pain Management

        10.4.3. Cardiovascular

        10.4.4. CNS Condition

        10.4.5. Oncology

        10.4.6. Diabetes

        10.4.7. Obesity

        10.4.8. Others

    10.5. Market Value Forecast, by Country, 2018–2030

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis 

        10.6.1. By Phase 

        10.6.2. By Study Design 

        10.6.3. By Indication 

        10.6.4. By Country

11. Europe Clinical Trials Market Analysis and Forecast

    11.1.Introduction

        11.1.1. Key Findings

    11.2.Market Value Forecast, by Phase, 2018–2030

        11.2.1. Phase I

        11.2.2. Phase II

        11.2.3. Phase III

        11.2.4. Phase IV

    11.3.Market Value Forecast, by Study Design, 2018–2030

        11.3.1. Interventional Trials

        11.3.2. Observational Trials

        11.3.3. Expanded Access Trials

    11.4.Market Value Forecast, by Indication, 2018–2030

        11.4.1. Autoimmune/Inflammation

        11.4.2. Pain Management

        11.4.3. Cardiovascular

        11.4.4. CNS Condition

        11.4.5. Oncology

        11.4.6. Diabetes

        11.4.7. Obesity

        11.4.8. Others

    11.5.Market Value Forecast, by Country/Sub-region, 2018–2030

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6.Market Attractiveness Analysis 

        11.6.1. By Phase 

        11.6.2. By Study Design 

        11.6.3. By Indication 

        11.6.4. By Country/Sub-region

12. Asia Pacific Clinical Trials Market Analysis and Forecast

    12.1.Introduction

        12.1.1. Key Findings

    12.2.Market Value Forecast, by Phase, 2018–2030

        12.2.1. Phase I

        12.2.2. Phase II

        12.2.3. Phase III

        12.2.4. Phase IV

    12.3.Market Value Forecast, by Study Design, 2018–2030

        12.3.1. Interventional Trials

        12.3.2. Observational Trials

        12.3.3. Expanded Access Trials

    12.4.Market Value Forecast, by Indication, 2018–2030

        12.4.1. Autoimmune/Inflammation

        12.4.2. Pain Management

        12.4.3. Cardiovascular

        12.4.4. CNS Condition

        12.4.5. Oncology

        12.4.6. Diabetes

        12.4.7. Obesity

        12.4.8. Others

    12.5.Market Value Forecast, by Country/Sub-region, 2018–2030

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6.Market Attractiveness Analysis 

        12.6.1. By Phase 

        12.6.2. By Study Design 

        12.6.3. By Indication 

        12.6.4. By Country/Sub-region

13. Latin America Clinical Trials Market Analysis and Forecast

    13.1.Introduction

        13.1.1. Key Findings

    13.2.Market Value Forecast, by Phase, 2018–2030

        13.2.1. Phase I

        13.2.2. Phase II

        13.2.3. Phase III

        13.2.4. Phase IV

    13.3.Market Value Forecast, by Study Design, 2018–2030

        13.3.1. Interventional Trials

        13.3.2. Observational Trials

        13.3.3. Expanded Access Trials

    13.4.Market Value Forecast, by Indication, 2018–2030

        13.4.1. Autoimmune/Inflammation

        13.4.2. Pain Management

        13.4.3. Cardiovascular

        13.4.4. CNS Condition

        13.4.5. Oncology

        13.4.6. Diabetes

        13.4.7. Obesity

        13.4.8. Others

    13.5.Market Value Forecast, by Country/Sub-region, 2018–2030

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6.Market Attractiveness Analysis 

        13.6.1. By Phase 

        13.6.2. By Study Design 

        13.6.3. By Indication 

        13.6.4. By Country/Sub-region

14. Middle East & Africa Clinical Trials Market Analysis and Forecast

    14.1.Introduction

        14.1.1. Key Findings

    14.2.Market Value Forecast, by Phase, 2018–2030

        14.2.1. Phase I

        14.2.2. Phase II

        14.2.3. Phase III

        14.2.4. Phase IV

    14.3.Market Value Forecast, by Study Design, 2018–2030

        14.3.1. Interventional Trials

        14.3.2. Observational Trials

        14.3.3. Expanded Access Trials

    14.4.Market Value Forecast, by Indication, 2018–2030

        14.4.1. Autoimmune/Inflammation

        14.4.2. Pain Management

        14.4.3. Cardiovascular

        14.4.4. CNS Condition

        14.4.5. Oncology

        14.4.6. Diabetes

        14.4.7. Obesity

        14.4.8. Others

    14.5.Market Value Forecast, by Country/Sub-region, 2018–2030

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6.Market Attractiveness Analysis 

        14.6.1. By Phase 

        14.6.2. By Study Design 

        14.6.3. By Indication 

        14.6.4. By Country/Sub-region

15. Competitive Landscape

    15.1. Market Player - Competition Matrix (by tier and size of companies)

    15.2. Market Share Analysis, by Company, 2019

    15.3. Company Profiles

        15.3.1. Laboratory Corporation of America Holdings

            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.1.2. Financial Overview

            15.3.1.3. Product Portfolio

            15.3.1.4. Strategic Overview

            15.3.1.5. SWOT Analysis

        15.3.2. IQVIA Inc.

            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.2.2. Financial Overview

            15.3.2.3. Product Portfolio

            15.3.2.4. Strategic Overview

            15.3.2.5. SWOT Analysis

        15.3.3. Syneos Health

            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.3.2. Financial Overview

            15.3.3.3. Product Portfolio

            15.3.3.4. Strategic Overview

            15.3.3.5. SWOT Analysis

        15.3.4. Parexel International Corporation 

            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.4.2. Financial Overview

            15.3.4.3. Product Portfolio

            15.3.4.4. Strategic Overview

            15.3.4.5. SWOT Analysis

        15.3.5. PPD Inc.

            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.5.2. Financial Overview

            15.3.5.3. Product Portfolio

            15.3.5.4. Strategic Overview

            15.3.5.5. SWOT Analysis

        15.3.6. Icon plc

            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.6.2. Financial Overview

            15.3.6.3. Product Portfolio

            15.3.6.4. Strategic Overview

            15.3.6.5. SWOT Analysis

        15.3.7. Charles River Laboratories, Inc.

            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.7.2. Financial Overview

            15.3.7.3. Product Portfolio

            15.3.7.4. Strategic Overview

            15.3.3.5. SWOT Analysis

        15.3.8. WuXi AppTec

            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.8.2. Financial Overview

            15.3.8.3. Product Portfolio

            15.3.8.4. Strategic Overview

            15.3.8.5. SWOT Analysis

        15.3.9. Medpace Holdings, Inc.

            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.9.2. Financial Overview

            15.3.9.3. Product Portfolio

            15.3.9.4. Strategic Overview

            15.3.9.5. SWOT Analysis

List of Tables

Table 01: Global Clinical Trials Market Value (US$ Mn) Forecast, by Phase, 2018–2030

Table 02: Global Clinical Trials Market Value (US$ Mn) Forecast, by Study Design, 2018–2030

Table 03: Global Clinical Trials Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 04: Global Clinical Trials Market Value (US$ Mn) Forecast, by Region, 2018–2030

Table 05: North America Clinical Trials Market Value (US$ Mn) Forecast, by Country, 2018–2030

Table 06: North America Clinical Trials Market Value (US$ Mn) Forecast, by Phase, 2018–2030

Table 07: North America Clinical Trials Market Value (US$ Mn) Forecast, by Phase, 2018–2030

Table 08: North America Clinical Trials Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 09: Europe Clinical Trials Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 10: Europe Clinical Trials Market Value (US$ Mn) Forecast, by Phase, 2018–2030

Table 11: Europe Clinical Trials Market Value (US$ Mn) Forecast, by Study Design, 2018–2030

Table 12: Europe Clinical Trials Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 13: Asia Pacific Clinical Trials Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 14: Asia Pacific Clinical Trials Market Value (US$ Mn) Forecast, by Phase, 2018–2030

Table 15: Asia Pacific Clinical Trials Market Value (US$ Mn) Forecast, by Study Design, 2018–2030

Table 16: Asia Pacific Clinical Trials Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 17: Latin America Clinical Trials Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 18: Latin America Clinical Trials Market Value (US$ Mn) Forecast, by Phase, 2018–2030

Table 19: Latin America Clinical Trials Market Value (US$ Mn) Forecast, by Study Design, 2018–2030

Table 20: Latin America Clinical Trials Market Value (US$ Mn) Forecast, by Indication, 2018–2030

Table 21: Middle East & Africa Clinical Trials Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

Table 22: Middle East & Africa Clinical Trials Market Value (US$ Mn) Forecast, by Phase, 2018–2030

Table 23: Middle East & Africa Clinical Trials Market Value (US$ Mn) Forecast, by Study Design, 2018–2030

Table 24: Middle East & Africa Clinical Trials Market Value (US$ Mn) Forecast, by Indication, 2018–2030

List of Figures

Figure 01: Global Clinical Trials Market Value (US$ Mn) Forecast, 2018–2030

Figure 02: Global Clinical Trials Market Value Share, by Phase, 2019

Figure 03: Global Clinical Trials Market Value Share, by Indication, 2019

Figure 04: Global Clinical Trials Market Value Share, by Study Design, 2019

Figure 05: Global Clinical Trials Market Value Share, by Region, 2019

Figure 06: Global Clinical Trials Market Value Share Analysis, by Phase, 2019 and 2030

Figure 07: Global Clinical Trials Market Value (US$ Mn), by Phase I, 2018–2030

Figure 08: Global Clinical Trials Market Value (US$ Mn), by Phase II, 2018–2030

Figure 09: Global Clinical Trials Market Value (US$ Mn), by Phase III, 2018–2030

Figure 10: Global Clinical Trials Market Value (US$ Mn), by Phase IV, 2018–2030

Figure 11: Global Clinical Trials Market Attractiveness Analysis, by Phase, 2020–2030

Figure 12: Global Clinical Trials Market Value Share Analysis, by Study Design, 2019 and 2030

Figure 13: Global Clinical Trials Market Value (US$ Mn), Interventional Trials, 2018–2030

Figure 14: Global Clinical Trials Market Value (US$ Mn), Observational Trials, 2018–2030

Figure 15: Global Clinical Trials Market Value (US$ Mn), Expanded Access Trials, 2018–2030

Figure 16: Global Clinical Trials Market Attractiveness Analysis, by Study Design, 2020–2030

Figure 17: Global Clinical Trials Market Value Share Analysis, by Indication, 2019 and 2030

Figure 18: Global Clinical Trials Market Value (US$ Mn), Autoimmune /Inflammation, 2018–2030

Figure 19: Global Clinical Trials Market Value (US$ Mn), Pain Management, 2018–2030

Figure 20: Global Clinical Trials Market Value (US$ Mn), Cardiovascular, 2018–2030

Figure 21: Global Clinical Trials Market Value (US$ Mn), CNS Condition, 2018–2030

Figure 22: Global Clinical Trials Market Value (US$ Mn), Oncology, 2018–2030

Figure 23: Global Clinical Trials Market Value (US$ Mn), Diabetes, 2018–2030

Figure 24: Global Clinical Trials Market Value (US$ Mn), Obesity, 2018–2030

Figure 25: Global Clinical Trials Market Value (US$ Mn), Others, 2018–2030

Figure 26: Global Clinical Trials Market Attractiveness Analysis, by Indication, 2020–2030

Figure 27: Global Clinical Trials Market Value Share Analysis, by Region, 2019 and 2030

Figure 28: Global Clinical Trials Market Attractiveness Analysis, by Region, 2020–2030

Figure 29: North America Clinical Trials Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

Figure 30: North America Clinical Trials Market Value Share (%), by Country, 2019 and 2030

Figure 31: North America Clinical Trials Market Attractiveness, by Country, 2020–2030

Figure 32: North America Clinical Trials Market Value Share Analysis, by Phase, 2019 and 2030

Figure 33: North America Clinical Trials Market Attractiveness Analysis, by Phase, 2020–2030

Figure 34: North America Clinical Trials Market Value Share Analysis, by Study Design, 2019 and 2030

Figure 35: North America Clinical Trials Market Attractiveness Analysis, by Study Design, 2020–2030

Figure 36: North America Clinical Trials Market Value Share Analysis, by Indication, 2019 and 2030

Figure 37: North America Clinical Trials Market Attractiveness Analysis, by Indication, 2020–2030

Figure 38: Europe Clinical Trials Market Value (US$ Mn) Forecast, 2018–2030

Figure 39: Europe Clinical Trials Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

Figure 40: Europe Clinical Trials Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 41: Europe Clinical Trials Market Value Share Analysis, by Phase, 2019 and 2030

Figure 42: Europe Clinical Trials Market Attractiveness Analysis, by Phase, 2020–2030

Figure 43: Europe Clinical Trials Market Value Share Analysis, by Study Design, 2019 and 2030

Figure 44: Europe Clinical Trials Market Attractiveness Analysis, by Study Design, 2020–2030

Figure 45: Europe Clinical Trials Market Value Share Analysis, by Indication, 2019 and 2030

Figure 46: Europe Clinical Trials Market Attractiveness Analysis, by Indication, 2020–2030

Figure 47: Asia Pacific Clinical Trials Market Value (US$ Mn) Forecast, 2018–2030

Figure 48: Asia Pacific Clinical Trials Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

Figure 49: Asia Pacific Clinical Trials Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 50: Asia Pacific Clinical Trials Market Value Share Analysis, by Phase, 2019 and 2030

Figure 51: Asia Pacific Clinical Trials Market Attractiveness Analysis, by Phase, 2020–2030

Figure 52: Asia Pacific Clinical Trials Market Value Share Analysis, by Study Design, 2019 and 2030

Figure 53: Asia Pacific Clinical Trials Market Attractiveness Analysis, by Study Design, 2020–2030

Figure 54: Asia Pacific Clinical Trials Market Value Share Analysis, by Indication, 2019 and 2030

Figure 55: Asia Pacific Clinical Trials Market Attractiveness Analysis, by Indication, 2020–2030

Figure 56: Latin America Clinical Trials Market Value (US$ Mn) Forecast, 2018–2030

Figure 57: Latin America Clinical Trials Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

Figure 58: Latin America Clinical Trials Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 59: Latin America Clinical Trials Market Value Share Analysis, by Phase, 2019 and 2030

Figure 60: Latin America Clinical Trials Market Attractiveness Analysis, by Phase, 2020–2030

Figure 61: Latin America Clinical Trials Market Value Share Analysis, by Study Design, 2019 and 2030

Figure 62: Latin America Clinical Trials Market Attractiveness Analysis, by Study Design, 2020–2030

Figure 63: Latin America Clinical Trials Market Value Share Analysis, by Indication, 2019 and 2030

Figure 64: Latin America Clinical Trials Market Attractiveness Analysis, by Indication, 2020–2030

Figure 65: Middle East & Africa Clinical Trials Market Value (US$ Mn) Forecast, 2018–2030

Figure 66: Middle East & Africa Clinical Trials Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

Figure 67: Middle East & Africa Clinical Trials Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

Figure 68: Middle East & Africa Clinical Trials Market Value Share Analysis, by Phase, 2019 and 2030

Figure 69: Middle East & Africa Clinical Trials Market Attractiveness Analysis, by Phase, 2020–2030

Figure 70: Middle East & Africa Clinical Trials Market Value Share Analysis, by Study Design, 2019 and 2030

Figure 71: Middle East & Africa Clinical Trials Market Attractiveness Analysis, by Study Design, 2020–2030

Figure 72: Middle East & Africa Clinical Trials Market Value Share Analysis, by Indication, 2019 and 2030

Figure 73: Middle East & Africa Clinical Trials Market Attractiveness Analysis, by Indication, 2020–2030

Figure 74: Global Clinical Trials Market Share Analysis, by Company, 2019

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Clinical Trials Market